We congratulate our client, Neuphoria Therapeutics Inc. on their successful redomiciliation to the U.S. In celebratory fashion, Neuphoria Therapeutics Inc. rang the Nasdaq Opening Bell on March 3rd, 2025!  Ted Ghorra, Andrew Reilly, Elaine Wangsawidjaja and Olivia Wang have worked regularly with this client. Read more here Rimon’s Securities and Capital Markets attorneys have decades…

A significant number of Australian and New Zealand issuers accessed the US capital markets in 2024. We have identified 145 US debt and equity offers that were completed by Australian and New Zealand issuers in 2024, with a median amount raised of A$100 million. The following graph shows the number of debt and equity offers…

Rimon is proud to have acted as US counsel to Bionomics Limited, an Australian clinical-stage biotechnology company, on its re-domiciliation to the United States and the successful listing of its new Delaware parent company (Neuphoria Therapeutics Inc.) on Nasdaq. Such a re-domiciliation involves an Australian statutory scheme of arrangement under which, following approval by shareholders…

We are pleased to announce the proposed business combination agreement between Rimon client, Australian Food & Agriculture Company Limited (AF&A), and Agriculture & Natural Solutions Acquisition Corporation, a special purpose acquisition company. Upon closing, the combined company, Agriculture & Natural Solutions Company Limited (“NewCo”), expects to be listed on the New York Stock Exchange (NYSE)…

Commencing January 2024, millions of companies must report beneficial ownership information (BOI) to the US Treasury’s Financial Crimes Enforcement Network (FinCEN) pursuant to the US Corporate Transparency Act (the CTA). The CTA was enacted to deter money laundering, financing of terrorism, tax fraud and other illegal acts by increasing transparency surrounding the control and ownership…

A significant number of Australian and New Zealand issuers accessed the US capital markets in 2023. We have identified 128 US debt and equity offers that were completed by Australian and New Zealand issuers in 2023, with a median amount raised of A$100 million. The following graph shows the number of debt and equity offers…

Rimon Law has acted as US counsel to Incannex Healthcare Limited, an ASX-listed Australian clinical stage company that is developing medicinal cannabis pharmaceutical products and psychedelic medicine therapies, on its re-domiciliation to Delaware with a listing on Nasdaq. Such a re-domiciliation involves an Australian statutory scheme of arrangement under which, following approval by shareholders and…

Rimon is proud to announce that two of its Partners have been honored by Who’s Who Legal. The following attorneys were recognized in 2023: Andrew Reilly – Global Leader: Capital Markets – Debt & Equity, National Leader: Australia & New Zealand – Capital Markets Sam Coppola – National Leader: Canada – Sports & Entertainment Who’s…

Rimon Partner, Andrew Reilly, explores the reasons why many U.S. companies choose to undertake an initial public offering (IPO) and list on the Australian Securities Exchange (ASX). Currently, over 20 U.S. incorporated companies and approximately 30 Australian incorporated companies with U.S. headquarters are listed on ASX. The purpose of this guide is to assist U.S.…

Rimon is proud to announce that two of its attorneys have been honored by Who’s Who Legal. The following attorneys were recognized in 2022: Andrew Reilly – Global Leader: Capital Markets – Debt & Equity, National Leader: Australia & New Zealand – Capital Markets Sam Coppola – National Leader: Canada – Sports & Entertainment Who’s…